Martin Jamieson, Chairman and CEO, Nexstim Plc commented: "We are extremely pleased to announce the launch of our NBT® system for depression at this TMS focused event. The unique navigational capability of our system, personalised to each patient for targeted stimulation of the relevant brain area, clearly differentiates it from the non-navigational TMS devices currently on the market for this indication."
TMS is FDA APPROVED for Treatment Resistant Major Depressive Disorder
WHAT IS IT?
Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. TMS is typically used when other depression treatments haven't been effective but can be used first if the patient wants to avoid medications (for a variety of reasons) and if the physician approves. (Please note that insurance is less likely to cover the service if used prior to medication)
There are promising results for other uses of TMS therapy in patients with ADHD, OCD, autism, tinnitus, neuropathic pain and other neuropsychiatric conditions. Trials are in progress for stroke rehabilitation and smoking cessation. While clinical studies are in progress and TMS is seen as experimental in some cases, we are also looking at our own data to help us determine which protocols are most effective for our patients.